From 1996 to 2000, 609 patients of acute leukemia in NIHBT, Bach Mai hospital were applied immunophenotype. The results as follow: Acute myeloid leukemia (AML): 408 patients (67%) including: AML (CD14-): 367patients (60.3%), AML (CD14+): 41patients (6.7%). Acute lymphoid leukemia (ALL): 123 patients (20.2%) including: PreT: 16 patients (2.6%), T: 3 patients (0.5%), Early B: 2 patients (0.3), PreB: 81 patients (13.3%), 21 patients (3.45%), 78 patients (only CD34+). NK acute leukemia: 1 patient (CD16/56+), Acute “null-cell” leukemia: 17 (all CDs negative on blasts), Mixed acute leute leukemia myoloid-B: 16 patients (CD13+, CD33+ and /or CD3; CD7+), Mixed acute leukemia myeloid-NK: 7 patients (CD13+, CD33+ and/or CD16/56+). These results contributed effectively to pathological study, folow up treatment and prognosis of acute leukemia
Leukemia ; immunology ; diagnosis

Chromosome analysis in bone marrow of leukemia patients and comparison of abnormalities between leukemia types classified by immunology using monoclonal antibodies showed that: There are chromosome abnormalities in 42 among 64 myeloid leukemia patients. Usual abnormalities are +8, t(8q; 21q+), t(15q+;17q-). In 17 lymphoblastic leukemia patients, there are 10 cases having chromosome abnormalities, the most frequent is t(9q+; 22q-). An acquired abnormalities (der 11q) added on constitutional abnormalities rob (14; 21) was detected in a myeloid leukemia patient
Leukemia ; immunology ; Chromosomes

Background: In Vietnam, there are increase rate of patients with acute leukemia including acute myelogenous leukemia. The clinical, gender, age as well as morphological characteristics of cells have prognostic significance about response to treatment and survival time of patients. Objectives: (1) To describe the distribution of acute myelogenous leukemia types by FAB standard in 'National Institute of Hematology and Blood Transfusion. (2) To describe the clinical characteristics of patients with acute myelogenous leukemia. Subjects and methods: The study included 67 patients diagnosed acute myelogenous leukemia by FAB standard without chemotherapy in 'National Institute of Hematology and Blood Transfusion. Results and conclusions: The median age: 35.55 \xb1 13.46, sex: 53% male, 47% female. Ratio of M0, M1, M2, M3, M4, M5, M6, M7 was 1, 10, 19, 18, 30, 13, 6, 1 %, respectively. 100% of these patients presented with anemia, 57 % with hemorrage, 46 % with fever. Lymphadenopathy was presented in 61 %, hepatomegaly was presented in 27% and spleenomegaly was presented in 9%. 53% of the patients had more bleeding was M3. Lymphadenopathy, hepatospleenomegaly had most frequently seen in the patients of M4 and M5 type. \r\n", u'\r\n', u'
Leukemia ; Myeloid ; Acute/ immunology ; Hematology

OBJECTIVETo investigate the role of Ara-C in regulating anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.

METHODSThe diabody of anti-CD3/anti-Pgp was purified by E-tag affinity chromatography. K562 and K562/A02 cells were treated with Ara-C. The expressions of B7-1 and B7-2 on K562 and K562/AO2 cells were detected by FACS. The cytotoxicity of T-lymphocytes combined with anti-CD3/anU-Pgp plus Ara-C was analyzed by CytoTox 96 nonradioactive method.

RESULTSThe expressions of B7-1 and B7-2 on K562 and K562/A02 cells treated by Ara-C was significantly higher than those untreated. The effect/target ratio was from 0.39:1 to 25:1, and the killing rate of activated T cells to anti-drug-resistant leukemia cells was from (16.44 +/- 1.20)% to (60.49 +/- 2.90)%. The killing rates were increased gradually, with both the effect/target ratio and the antibody concentration increasing (P < 0.05).

CONCLUSIONAra-C may be an important adjuvant for improving anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.

Dendritic cells can be derived from leukemia cells and normal precursor cells in the patients with acute myeloid leukemia (AML). Dendritic cells may capture leukemia antigen in bone marrow or lymph nodes, and present leukemia common antigen to stimulate proliferation of specific CD8(+) T cells, playing anti-leukemia effect. Dendritic cells for clinical and experimental use are transformed from leukemia cells and peripheral blood mononuclear cells and loaded in vitro with leukemia -specific or tumor common antigen, play a therapeutic role after reinfusion. This article reviews dendritic cells in the immunotherapy of AML.
Dendritic Cells ; immunology ; Humans ; Immunotherapy ; Leukemia, Myeloid, Acute ; immunology ; therapy

To explore the relationship between T cell markers in hematological diseases and T cell markers in solid tumor, CD3, CD4, CD8 in hematological diseases, malignant and benign tumors were detected by flow cytometry and results were analyzed statistically. The results showed that CD3, CD4, CD8 and CD4/CD8 in chronic leukemia decreased significantly while these markers in acute leukemia and MDS decreased obviously in comparison with normal persons and other hematological diseases (P < 0.0l). Hemolytic anemia markers increased significantly (P < 0.05). CD3, CD4, CD4/CD8 in idiopathic thrombocytopenic purpura decreased and CD8 increased (P < 0.0l). CD3, CD4, CD8 in iron-deficiency anemia, anemia from chronic diseases, benign tumor and other hematological diseases were lower than those in normal persons and hemolytic anemia, but higher than those in acute and chronic leukemia, malignant tumor, granulocytopenia, and MDS (P > 0.05). It is notable that the above markers correlated with the development and prognosis of diseases. In conclusion, expression of CD3, CD4, CD8, CD4/CD8 contributes to diagnosis of hematological diseases and benign or malignant tumors, and is an important indicator for therapeutic strategy.
Anemia ; immunology ; CD4-CD8 Ratio ; Hematologic Diseases ; immunology ; Humans ; Leukemia ; immunology ; Myelodysplastic Syndromes ; immunology ; Neoplasms ; immunology ; T-Lymphocyte Subsets ; immunology

Over a two-year period, immunophenotypic patterns of 266 acute leukemia cases were analyzed using a panel of tests including TdT, SmIg and 9 surface antigens by the immunofluorescence stains for the assessment of the incidence and grade of phenotypic ambiguity (lineage infidelity) and the possible clinical significance of unusual immunophenotypes. Immunophenotypes were classified into four groups according to the degree of ectopic antigen expression. We classified as Group A (91.7%, 244 of 266 cases) those expressing conventional pattern without ectopic antigen. Group B (3.0%, 8 of 266 cases) was defined to have at least two lineage specific markers and single ectopic antigen. Such a "low grade deviation" did not prevent a definite immunodiagnosis. Group C (4.2%, 11 of 266 cases) revealed a promiscuous coexpression of markers related to different lineages, including two cases (0.8%, 2 cases) of biphenotypic leukemia. Group D (1.1%, 3 cases) included unclassifiable immunophenotypes with no antigen or HLA-DR only expression. Both patients with biphenotypic leukemia and one patient with unclassifiable immunophenotypes failed to respond to induction chemotherapy, suggesting a poor prognosis in these patients. The incidence of acute myelogenous leukemia (AML) cases with one or more ectopic surface antigens was 10 (8.1%) of the 124 AML cases. Ectopic antigen expression was seen in 5 (4%) of the 125 B-lineage acute lymphoblastic leukemia (ALL) cases and 3 (25%) of the 12 T-ALL cases. It is concluded that nearly 95% of cases of acute leukemia cases can be diagnosed accurately with immunophenotyping alone including patients with a mild degree of deviation from expected antigenic patterns.(ABSTRACT TRUNCATED AT 250 WORDS)
Acute Disease ; Antigens, Differentiation/blood ; Burkitt Lymphoma/immunology ; Humans ; Immunophenotyping ; Leukemia/*immunology ; Leukemia, Myeloid/immunology ; Leukemia-Lymphoma, Adult T-Cell/immunology ; Retrospective Studies

Angiopoietin2( ANGPT2 ) plays an important role in tumor angiopoiesis. ANGPT2 antagonises ANGPT1 resulting in an effect on the stability of blood vessels, which promotes tumor growth, invasion, proliferation as well as relating to tumor vascular density. A lot of researches published papers about anti-ANGPT2 for the treatment of tumor, and have made some progresses. In this review, the role of ANGPT2 in the pathogenesis of acute myelogenous leukemia (AML), including its effects on proliferation of leukemia cells, bone marrow angiopoiesis, tumor invasion and metastasis are briefly summarised in order to provide the basis for targeted ANGPT2 in treatment of AML.
Angiopoietin-1 ; immunology ; Antibodies ; immunology ; Bone Marrow ; Humans ; Leukemia, Myeloid, Acute ; immunology ; Neoplasm Invasiveness ; Neoplasm Metastasis

The aim was to investigate the cytolytic activity of cytotoxic T lymphocytes (CTL) induced by dendritic cells (DC) derived from human cord blood in vitro. Human cord blood mononuclear cells (CBMNC) were cultured in vitro with addition of various cytokines. DC was confirmed by morphology, immune phenotype and capacity of stimulating MLR (mixed lymphocyte reaction). CTL were generated through the co-culture of autologous T lymphocytes and DC. (51)Cr-release assays were performed for the measurement of cytotoxicity of CTL. The results showed that distribution of the subgroups of T lymphocytes in CBMNC was similar to that in adult peripheral blood. The percentage of CD1a-expressing cells in CBMNC was very low, merely (0.41 +/- 0.09)%. During culture, DC became larger and more irregular in shape. Spiny dendrites or multiple cell processes in morphology emerged on the surface of DC. Among the cell populations at 15 days of culture, there were (28.4 +/- 3.55)% of CD1a-expressing cells, (63.67 +/- 23.33)% of CD86-positive, (8.7 +/- 1.49)% of CD83-positive and (32.5 +/- 1.53)% of HLA-DR-positive cells. DC derived from CBMNC is capable of stimulating the proliferation of allogeneic lymphocytes in MLR. CTL derived from autologous T lymphocytes induced by dendritic cells pulsed with lysates of HL-60 cells, possessed specific cytolytic effects against HL-60 cells. In conclusions, relatively high percentage of CD1a-expressing cells can be generated in culture system of this study. DC derived from cord blood is able to induce the production of anti-leukemic CTL in vitro.
Antigens, CD1 ; analysis ; Cytotoxicity, Immunologic ; Dendritic Cells ; immunology ; Fetal Blood ; immunology ; Humans ; Immunophenotyping ; Leukemia ; immunology ; T-Lymphocytes, Cytotoxic ; immunology

Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens (LAA) that are recognized by cytotoxic T cell (CTL) in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer (DC-CIK) cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.
Humans ; Immunotherapy, Adoptive ; Leukemia ; therapy ; T-Lymphocytes, Cytotoxic ; immunology